Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210)
    Meeting Abstract

    Rosenberg, J. E.; Petrylak, D. P.; Van Der Heijden, M. S.; Necchi, A.; O'Donnell, P. H.; Loriot, Y.; Retz, M.; Perez-Gracia, J. L.; Bellmunt, J.; Grivas, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa)
    Meeting Abstract

    Pomerantz, M.; Wang, X. V.; Kantoff, P. W.; Xie, W.; Kohli, M.; Lee, G. S. M.; Wang, E.; Chen, Y. H.; Hahn, N. M.; Jarrard, D. F.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Powles, T.; Motzer, R. J.; Escudier, B. J.; Pal, S. K.; Kollmannsberger, C. K.; Pikiel, J.; Gurney, H.; Rha, S. Y.; Park, S. H.; Geertsen, P. F.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Correlation between platelet/lymphocyte ratio, neutrophil/lymphocyte ratio and response to neoadjuvant chemoradiation therapy in rectal cancer
    Meeting Abstract

    Picardo, S. L.; Teo, M.; Jalil, K. I. A.; Naqvi, S. Y.; Morris, P. G.; Breathnach, O. S.; Grogan, W.; Leonard, G. D.; Hennessy, B.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • The role for resection of post-chemotherapy residual liver masses in the management of non-seminomatous germ cell tumor
    Meeting Abstract

    Pietzak, E. J.; Assel, M.; Tennenbaum, D. M.; Becerra, M.; Feldman, D. R.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; Carver, B. S.; Sjoberg, D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Differences in somatic DNA damage repair (DDR) gene alterations between primary and secondary muscle invasive bladder cancer (MIBC)
    Meeting Abstract

    Pietzak, E. J.; Bagrodia, A.; Li, Q.; Al-Ahmadie, H.; Herr, H. W.; Funt, S.; Barron, D.; Zehir, A.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC)
    Meeting Abstract

    Patel, V. G.; McBride, R. B.; Lorduy, A. C.; Castillo-Martin, M.; Cha, E. K.; Berger, M. F.; Wang, L.; Oh, W. K.; Zhu, J.; Cordon-Cardo, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations
    Meeting Abstract

    Pal, S. K.; Rosenberg, J. E.; Keam, B.; Wolf, J.; Berger, R.; Dittrich, C.; Hoffman-Censits, J. H.; Quinn, D.; van der Noll, R.; Burris, H. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer
    Meeting Abstract

    Papadopoulos, K. P.; Naing, A.; Infante, J. R.; Autio, K. A.; Ott, P. A.; Wong, D. J. L.; Falchook, G. S.; Patel, M. R.; Pant, S.; Whiteside, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save